BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• 

  Drug Development

  Eyedrop Version of Krystal’s Gene Therapy Vyjuvek Restores Sight in Teen

  Under the FDA’s compassionate use program, an eyedrop formulation of Krystal Biotech’s Vyjuvek restored the vision of a teenager with the rare genetic disease dystrophic epidermolysis bullosa.

  February 8, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  Kyowa Kirin Pays $100M Upfront to BridgeBio for Skeletal Dysplasias Drug in Japan

  Kyowa Kirin’s dealmaking continued on Wednesday when BridgeBio Pharma granted the Japanese company an exclusive license to develop and commercialize infigratinib.

  February 8, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Business

  AstraZeneca Sees 6% Revenue Growth in 2023 Despite Plummeting COVID-19 Sales

  Thursday’s full-year financial results from AstraZeneca showed a revenue crash of more than 90% for COVID-19 medicines, while cancer, cardiovascular and rare diseases all generated double-digit revenue growth.

  February 8, 2024

   · 

  3 min read

   · 

  Tristan Manalac
• 

  Deals

  Kyverna’s $319M Upsized IPO Is Latest in Surge of Biotechs Going Public

  On Thursday, Kyverna Therapeutics is debuting on the Nasdaq with an upsized initial public offering which the biotech will use to support its pipeline of anti-CD19 CAR T therapy candidates.

  February 8, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Business

  BioNTech Inks $250M Deal with Autolus to Advance CAR-T Assets

  BioNTech will pay $50 million in cash and purchase $200 million of Autolus Therapeutics’ shares to progress the companies’ respective CAR-T candidates to commercialization.

  February 8, 2024

   · 

  2 min read

   · 

  Tyler Patchen
• 

  Policy

  EU Regulator Investigates Potential Impacts of Novo-Catalent Deal on Drug Supply

  The European Medicines Agency is looking into how Novo Holdings’ recently announced $16.5 billion acquisition of contract manufacturer Catalent might affect the availability of drugs.

  February 8, 2024

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Drug Development

  Gilead Axes Blood Cancer Treatment After Risk of Death Identified by FDA

  Gilead Sciences is ending the development of magrolimab for the treatment of blood cancer following the FDA’s placement of a clinical hold on all its programs related to the drug.

  February 8, 2024

   · 

  1 min read

   · 

  Tyler Patchen
• Press Releases

  Sana Biotechnology Announces Pricing of Upsized Public Offering - February 08, 2024

  Sana Biotechnology, Inc. announced that it has priced its underwritten upsized public offering of 17,272,728 shares of its common stock at a price to the public of $5.50 per share.

  February 8, 2024

   · 

  3 min read
• Business

  BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs

  BioNTech SE and Autolus Therapeutics plc announced a strategic collaboration aimed at advancing both companies’ autologous CAR-T programs towards commercialization, pending regulatory authorizations.

  February 8, 2024

   · 

  14 min read
• Business

  Veru Reports Fiscal 2024 First Quarter Financial Highlights

  Veru Inc. today announced financial highlights for its fiscal 2024 first quarter and provided a business update.

  February 8, 2024

   · 

  13 min read